BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shen H, Hu D, Du J, Wang X, Liu Y, Wang Y, Wei J, Ma D, Wang P, Li L. Paclitaxel–octreotide conjugates in tumor growth inhibition of A549 human non-small cell lung cancer xenografted into nude mice. European Journal of Pharmacology 2008;601:23-9. [DOI: 10.1016/j.ejphar.2008.10.035] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Wang L, Chen H, Wang F, Zhang X. The development of peptide-drug conjugates (PDCs) strategies for paclitaxel. Expert Opin Drug Deliv 2022. [PMID: 35130795 DOI: 10.1080/17425247.2022.2039621] [Reference Citation Analysis]
2 Liu Y, Xia H, Wang Y, Han W, Qin J, Gao W, Qu X, Wang X. Targeted paclitaxel-octreotide conjugates inhibited the growth of paclitaxel-resistant human non-small cell lung cancer A549 cells in vitro. Thorac Cancer 2021;12:3053-61. [PMID: 34617400 DOI: 10.1111/1759-7714.14182] [Reference Citation Analysis]
3 Hoppenz P, Els-Heindl S, Beck-Sickinger AG. Peptide-Drug Conjugates and Their Targets in Advanced Cancer Therapies. Front Chem 2020;8:571. [PMID: 32733853 DOI: 10.3389/fchem.2020.00571] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 11.0] [Reference Citation Analysis]
4 Worm DJ, Els‐heindl S, Beck‐sickinger AG. Targeting of peptide‐binding receptors on cancer cells with peptide‐drug conjugates. Peptide Science 2020;112. [DOI: 10.1002/pep2.24171] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
5 Wang Y, Wen X, Zhang N, Wang L, Hao D, Jiang X, He G. Small-molecule compounds target paraptosis to improve cancer therapy. Biomed Pharmacother 2019;118:109203. [PMID: 31306970 DOI: 10.1016/j.biopha.2019.109203] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
6 Jiang Z, Guan J, Qian J, Zhan C. Peptide ligand-mediated targeted drug delivery of nanomedicines. Biomater Sci 2019;7:461-71. [PMID: 30656305 DOI: 10.1039/c8bm01340c] [Cited by in Crossref: 54] [Cited by in F6Publishing: 20] [Article Influence: 18.0] [Reference Citation Analysis]
7 Klahn P, Fetz V, Ritter A, Collisi W, Hinkelmann B, Arnold T, Tegge W, Rox K, Hüttel S, Mohr KI, Wink J, Stadler M, Wissing J, Jänsch L, Brönstrup M. The nuclear export inhibitor aminoratjadone is a potent effector in extracellular-targeted drug conjugates. Chem Sci 2019;10:5197-210. [PMID: 31191875 DOI: 10.1039/c8sc05542d] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
8 Chatzisideri T, Leonidis G, Sarli V. Cancer-targeted delivery systems based on peptides. Future Med Chem 2018;10:2201-26. [PMID: 30043641 DOI: 10.4155/fmc-2018-0174] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
9 Sun Y, Wu P, Sun Y, Sharopov FS, Yang Q, Chen F, Wang P, Liang Z. Lycorine possesses notable anticancer potentials in on-small cell lung carcinoma cells via blocking Wnt/β-catenin signaling and epithelial-mesenchymal transition (EMT). Biochem Biophys Res Commun 2018;495:911-21. [PMID: 29127013 DOI: 10.1016/j.bbrc.2017.11.032] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
10 Khan M, Huang T, Lin CY, Wu J, Fan BM, Bian ZX. Exploiting cancer's phenotypic guise against itself: targeting ectopically expressed peptide G-protein coupled receptors for lung cancer therapy. Oncotarget 2017;8:104615-37. [PMID: 29262666 DOI: 10.18632/oncotarget.18403] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
11 Bharti R, Dey G, Banerjee I, Dey KK, Parida S, Kumar BN, Das CK, Pal I, Mukherjee M, Misra M, Pradhan AK, Emdad L, Das SK, Fisher PB, Mandal M. Somatostatin receptor targeted liposomes with Diacerein inhibit IL-6 for breast cancer therapy. Cancer Lett 2017;388:292-302. [PMID: 28025102 DOI: 10.1016/j.canlet.2016.12.021] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 6.0] [Reference Citation Analysis]
12 Li H, Yuan D, Sun M, Ping Q. Effect of ligand density and PEG modification on octreotide-targeted liposome via somatostatin receptor in vitro and in vivo. Drug Delivery 2016;23:3562-72. [DOI: 10.1080/10717544.2016.1209797] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
13 Wang T, Zabarska N, Wu Y, Lamla M, Fischer S, Monczak K, Ng DY, Rau S, Weil T. Receptor selective ruthenium-somatostatin photosensitizer for cancer targeted photodynamic applications. Chem Commun (Camb) 2015;51:12552-5. [PMID: 26153573 DOI: 10.1039/c5cc03473f] [Cited by in Crossref: 63] [Cited by in F6Publishing: 13] [Article Influence: 10.5] [Reference Citation Analysis]
14 Zhang HY, Xu WQ, Wang YW, Omari-Siaw E, Wang Y, Zheng YY, Cao X, Tong SS, Yu JN, Xu XM. Tumor targeted delivery of octreotide-periplogenin conjugate: Synthesis, in vitro and in vivo evaluation. Int J Pharm 2016;502:98-106. [PMID: 26899980 DOI: 10.1016/j.ijpharm.2016.02.024] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
15 Böhme D, Beck-Sickinger AG. Drug delivery and release systems for targeted tumor therapy. J Pept Sci 2015;21:186-200. [PMID: 25703117 DOI: 10.1002/psc.2753] [Cited by in Crossref: 70] [Cited by in F6Publishing: 67] [Article Influence: 10.0] [Reference Citation Analysis]
16 Zheng N, Dai W, Zhang H, Wang X, Wang J, Zhang X, Wang K, Li J, Zhang Q. Lanreotide-conjugated PEG-DSPE micelles: an efficient nanocarrier targeting to somatostatin receptor positive tumors. J Drug Target 2015;23:67-78. [PMID: 25366085 DOI: 10.3109/1061186X.2014.954118] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
17 Duskey JT, Rice KG. Nanoparticle ligand presentation for targeting solid tumors. AAPS PharmSciTech 2014;15:1345-54. [PMID: 24927668 DOI: 10.1208/s12249-014-0143-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
18 Rosenkranz AA, Ulasov AV, Slastnikova TA, Khramtsov YV, Sobolev AS. Use of intracellular transport processes for targeted drug delivery into a specified cellular compartment. Biochemistry Moscow 2014;79:928-46. [DOI: 10.1134/s0006297914090090] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
19 Akhtar MJ, Ahamed M, Alhadlaq HA, Alrokayan SA, Kumar S. Targeted anticancer therapy: Overexpressed receptors and nanotechnology. Clinica Chimica Acta 2014;436:78-92. [DOI: 10.1016/j.cca.2014.05.004] [Cited by in Crossref: 119] [Cited by in F6Publishing: 101] [Article Influence: 14.9] [Reference Citation Analysis]
20 He S, Zhou Z, Li L, Yang Q, Yang Y, Guan S, Zhang J, Zhu X, Jin Y, Huang Y. Comparison of active and passive targeting of doxorubicin for somatostatin receptor 2 positive tumor models by octreotide-modified HPMA copolymer-doxorubicin conjugates. Drug Deliv 2016;23:285-96. [PMID: 24865288 DOI: 10.3109/10717544.2014.911991] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
21 Monroy-Estrada HI, Chirino YI, Soria-Mercado IE, Sánchez-Rodríguez J. Toxins from the Caribbean sea anemone Bunodeopsis globulifera increase cisplatin-induced cytotoxicity of lung adenocarcinoma cells. J Venom Anim Toxins Incl Trop Dis 2013;19:12. [PMID: 24499018 DOI: 10.1186/1678-9199-19-12] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
22 Meenach SA, Shapiro JM, Hilt JZ, Anderson KW. Characterization of PEG-iron oxide hydrogel nanocomposites for dual hyperthermia and paclitaxel delivery. J Biomater Sci Polym Ed 2013;24:1112-26. [PMID: 23683041 DOI: 10.1080/09205063.2012.741321] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 3.5] [Reference Citation Analysis]
23 Williamson EA, Damiani L, Leitao A, Hu C, Hathaway H, Oprea T, Sklar L, Shaheen M, Bauman J, Wang W, Nickoloff JA, Lee SH, Hromas R. Targeting the transposase domain of the DNA repair component Metnase to enhance chemotherapy. Cancer Res 2012;72:6200-8. [PMID: 23090115 DOI: 10.1158/0008-5472.CAN-12-0313] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
24 Dai W, Jin W, Zhang J, Wang X, Wang J, Zhang X, Wan Y, Zhang Q. Spatiotemporally Controlled Co-delivery of Anti-vasculature Agent and Cytotoxic Drug by Octreotide-Modified Stealth Liposomes. Pharm Res 2012;29:2902-11. [DOI: 10.1007/s11095-012-0797-2] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 3.4] [Reference Citation Analysis]
25 Zheng N, Dai W, Du W, Zhang H, Lei L, Zhang H, Wang X, Wang J, Zhang X, Gao J, Zhang Q. A Novel Lanreotide-Encoded Micelle System Targets Paclitaxel to the Tumors with Overexpression of Somatostatin Receptors. Mol Pharmaceutics 2012;9:1175-88. [DOI: 10.1021/mp200464x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
26 Galer CE, Sano D, Ghosh SC, Hah JH, Auzenne E, Hamir AN, Myers JN, Klostergaard J. Hyaluronic acid-paclitaxel conjugate inhibits growth of human squamous cell carcinomas of the head and neck via a hyaluronic acid-mediated mechanism. Oral Oncol 2011;47:1039-47. [PMID: 21903450 DOI: 10.1016/j.oraloncology.2011.07.029] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
27 Su Z, Niu J, Xiao Y, Ping Q, Sun M, Huang A, You W, Sang X, Yuan D. Effect of octreotide-polyethylene glycol(100) monostearate modification on the pharmacokinetics and cellular uptake of nanostructured lipid carrier loaded with hydroxycamptothecine. Mol Pharm 2011;8:1641-51. [PMID: 21770405 DOI: 10.1021/mp100463n] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 4.4] [Reference Citation Analysis]
28 Zhang J, Jin W, Wang X, Wang J, Zhang X, Zhang Q. A novel octreotide modified lipid vesicle improved the anticancer efficacy of doxorubicin in somatostatin receptor 2 positive tumor models. Mol Pharm. 2010;7:1159-1168. [PMID: 20524673 DOI: 10.1021/mp1000235] [Cited by in Crossref: 79] [Cited by in F6Publishing: 82] [Article Influence: 6.6] [Reference Citation Analysis]
29 Mezo G, Manea M. Receptor-mediated tumor targeting based on peptide hormones. Expert Opin Drug Deliv 2010;7:79-96. [PMID: 19947889 DOI: 10.1517/17425240903418410] [Cited by in Crossref: 67] [Cited by in F6Publishing: 63] [Article Influence: 5.6] [Reference Citation Analysis]
30 Lin MM, Kim H, Kim H, Dobson J, Kim DK. Surface activation and targeting strategies of superparamagnetic iron oxide nanoparticles in cancer-oriented diagnosis and therapy. Nanomedicine 2010;5:109-33. [DOI: 10.2217/nnm.09.96] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 3.1] [Reference Citation Analysis]